| Biomarker ID | 1755 |
| PMID | 30288742 |
| Year | 2018 |
| Biomarker | AZGP1; Ki67; PML |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | AZGP1: 2.9 (95% CI: 1.4-5.6); Ki67: 3.0 (95% CI: 1.0-9.4); PML: 2.1 (95% CI: 1.0-4.1) |
| Effect on Pathways | NA |
| Experiment | Metastatic Relapse Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | Discovery Cohort consisted of 324 patients, out of which 147 experienced Biochemical Relapse, 34 experienced metastatic Relapse, and 16 had prostate cancer related deaths. Validation Cohort consisted of 347 patients, out of which 55 experienced Biochemical Relapse, 18 experienced metastatic Relapse, and 5 had prostate cancer related deaths. Results shown for discovery cohort |
| Senstivity | NA |
| Specificity | NA |
| AUC | Unadjusted: AZGP1: 0.639 (95% CI: 0.535-0.744) ; Ki67: 0.531 (95% CI: 0.429-0.633); PML: 0.586 (95% CI: 0.492-0.680)Adjusted for grade group and P-stage: AZGP1: 0.749 (95% CI: 0.660-0.838); Ki67: 0.717 (95% CI: 0.629-0.806); PML: 0.726 (95% CI: 0.636-0.817) |
| Accuracy | NA |
| Level Of Significance | AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |